These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 15015608)

  • 1. Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer.
    Oi K; Makino M; Ozaki M; Takemoto H; Yamane N; Nakamura S; Ikeguchi M; Kaibara N
    Anticancer Res; 2004; 24(1):273-9. PubMed ID: 15015608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic effects of dihydropyrimidine dehydrogenase in advanced colorectal cancer after surgery: immunohistochemistry using a new monoclonal antibody.
    Tokunaga Y; Nakagami M; Tokuka A; Ohsumi K
    Anticancer Res; 2003; 23(2C):1763-8. PubMed ID: 12820455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
    Tokunaga Y; Takahashi K; Saito T
    Hepatogastroenterology; 2005; 52(66):1715-21. PubMed ID: 16334763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer.
    Tsuji T; Sawai T; Takeshita H; Nakagoe T; Hidaka S; Yamaguchi H; Yasutake T; Nagayasu T; Tagawa Y
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):531-6. PubMed ID: 15309506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance.
    Oeda M; Yoshida K; Sanada Y; Wada Y; Suzuki T; Mizuiri H; Konishi K; Shigematsu H; Tanabe K; Fukushima M
    Oncol Rep; 2006 Dec; 16(6):1165-72. PubMed ID: 17089033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
    Tokunaga Y; Sasaki H; Saito T
    Surgery; 2007 Mar; 141(3):346-53. PubMed ID: 17349846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DPD activity and immunohistochemical DPD expression in human breast cancer.
    Horiguchi J; Yoshida T; Koibuchi Y; Iijima K; Ninomiya J; Takei H; Yokoe T; Iino Y; Morishita Y
    Oncol Rep; 2004 Jan; 11(1):65-72. PubMed ID: 14654904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy.
    Huang CL; Yokomise H; Kobayashi S; Fukushima M; Hitomi S; Wada H
    Int J Oncol; 2000 Jul; 17(1):47-54. PubMed ID: 10853017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer.
    Nakayama Y; Inoue Y; Nagashima N; Katsuki T; Matsumoto K; Kadowaki K; Shibao K; Tsurudome Y; Hirata K; Sako T; Nagata N; Itoh H
    Anticancer Res; 2005; 25(6A):3755-61. PubMed ID: 16302736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
    Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between survival and the expression of dihydropyrimidine dehydrogenase in patients with colorectal cancer.
    Hotta T; Takifuji K; Taniguchi K; Sahara M; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
    Oncol Rep; 2006 Jul; 16(1):177-82. PubMed ID: 16786143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatic recurrence after prophylactic hepatic arterial infusion of 5-fluorouracil for Dukes' C colorectal cancer--correlation with the expression of dihydropyrimidine dehydrogenase in the primary tumor].
    Ishida H; Takeuchi I; Ohsawa T; Nakada H; Ishizuka N; Yokoyama M; Inokuma S; Suzuki T; Yamada H; Odaka A; Hoshino T; Murata N; Hashimoto D; Matsumoto Y; Miura T
    Gan To Kagaku Ryoho; 2002 Nov; 29(12):2267-70. PubMed ID: 12484051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence and 5-FU sensitivity of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses.
    Mukai M; Sato S; Ninomiya H; Wakui K; Komatsu N; Tsuchiya K; Nakasaki H; Makuuchi H
    Oncol Rep; 2005 Nov; 14(5):1165-9. PubMed ID: 16211280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy.
    Kamoshida S; Matsuoka H; Ishikawa T; Maeda K; Shimomura R; Inada K; Tsutsumi Y
    Jpn J Clin Oncol; 2004 Oct; 34(10):594-601. PubMed ID: 15591457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of two fluorouracil administration regimens for colorectal cancer.
    Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
    Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of dihydropyrimidine dehydrogenase in human colorectal carcinoma and its clinical implications].
    Xiao JX; Han M; Li L; Zhu J; Chen LH; Bai PS
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2136-9. PubMed ID: 16313827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.
    Kinoshita M; Kodera Y; Hibi K; Nakayama G; Inoue T; Ohashi N; Ito Y; Koike M; Fujiwara M; Nakao A
    Anticancer Res; 2007; 27(2):851-6. PubMed ID: 17465211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.